PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000850912.43010.d3 |
| _version_ | 1827335156657029120 |
|---|---|
| author | M. V. Mateos N. Bahlis L. Costa A. Perrot L. Pei M. Rubin K. Lantz W. Sun M. Jaffe R. Kobos A. Nooka |
| author_facet | M. V. Mateos N. Bahlis L. Costa A. Perrot L. Pei M. Rubin K. Lantz W. Sun M. Jaffe R. Kobos A. Nooka |
| author_sort | M. V. Mateos |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:10:20Z |
| format | Article |
| id | doaj.art-68b785c67bda484fa6d6a1f7dbbf5809 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:10:20Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-68b785c67bda484fa6d6a1f7dbbf58092024-03-02T07:47:23ZengWileyHemaSphere2572-92412022-06-0161891189210.1097/01.HS9.0000850912.43010.d3202206003-01891PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMAM. V. Mateos0N. Bahlis1L. Costa2A. Perrot3L. Pei4M. Rubin5K. Lantz6W. Sun7M. Jaffe8R. Kobos9A. Nooka101 Hospital Clínico Universitario de Salamanca, Salamanca, Spain2 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada3 University of Alabama at Birmingham, Birmingham, United States of America4 Centre Hospitalier Universitaire de Toulouse, Service d’Hématologie, Toulouse, France5 Janssen Research & Development, Raritan6 Janssen Research & Development, Spring House6 Janssen Research & Development, Spring House7 Janssen Research & Development, Los Angeles5 Janssen Research & Development, Raritan5 Janssen Research & Development, Raritan8 Winship Cancer Institute, Emory University, Atlanta, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000850912.43010.d3 |
| spellingShingle | M. V. Mateos N. Bahlis L. Costa A. Perrot L. Pei M. Rubin K. Lantz W. Sun M. Jaffe R. Kobos A. Nooka PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA HemaSphere |
| title | PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full | PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_short | PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_sort | pb2020 majestec 3 randomized phase 3 study of teclistamab plus daratumumab versus dpd or dvd in patients with relapsed refractory multiple myeloma |
| url | http://journals.lww.com/10.1097/01.HS9.0000850912.43010.d3 |
| work_keys_str_mv | AT mvmateos pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT nbahlis pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT lcosta pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT aperrot pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT lpei pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT mrubin pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT klantz pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT wsun pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT mjaffe pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT rkobos pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT anooka pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma |